Limits...
MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer.

Suzuki S, Sasajima K, Sato Y, Watanabe H, Matsutani T, Iida S, Hosone M, Tsukui T, Maeda S, Shimizu K, Tajiri T - Br. J. Cancer (2008)

Bottom Line: Both protein and gene showed significantly higher expression in group A than those in groups B (6.7, 26.7%) and C (0, 0%) (P=0.0003, P=<0.0001, respectively).MAGE-A10 gene expression was associated with reduced survival duration.The results of this study suggest that MAGE-A10 is a possible target in active immunotherapy for advanced stomach cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Tama-Nagayama Hospital, Nippon Medical School, Tama, Tokyo, Japan. seiji@nms.ac.jp

ABSTRACT
Tumour samples from 71 patients with stomach cancer, 41 patients with liver metastasis (group A) and 15 patients each in stages II-IV (group B) and stage I (group C) without liver metastasis were analysed. MAGE-A protein expression was evaluated by immunohistochemistry using a 6C1 monoclonal antibody and MAGE-A10 mRNA expression was detected by highly sensitive in situ hybridisation using a cRNA probe. Expressions of MAGE-A protein and MAGE-A10 mRNA in group A were detected in 65.9 and 80.5%, respectively. Both protein and gene showed significantly higher expression in group A than those in groups B (6.7, 26.7%) and C (0, 0%) (P=0.0003, P=<0.0001, respectively). MAGE-A10 mRNA expression in liver metastasis was found in eight (88.9%) out of nine patients. The concordant rate between MAGE-A family protein expression and MAGE-A10 mRNA expression in the primary sites was 81.7% (P<0.0001). MAGE-A10 gene expression was associated with reduced survival duration. The results of this study suggest that MAGE-A10 is a possible target in active immunotherapy for advanced stomach cancer.

Show MeSH

Related in: MedlinePlus

Relationship between MAGE-A family protein (A) and MAGE-A10 mRNA (B) expression and survival duration in all cases.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2480964&req=5

fig3: Relationship between MAGE-A family protein (A) and MAGE-A10 mRNA (B) expression and survival duration in all cases.

Mentions: Kaplan–Meier analysis revealed that group A had significantly shorter survival duration than groups B and C (P<0.0001, each). A 5-year survival rate was 6% in group A, 87% in group B and 100% in group C. Patients with MAGE-A protein and MAGE-A10 gene expression had poor outcome (P<0.0001, each) (Figure 3A and 3B). Only three patients with MAGE-A10 gene expression survived more than 5 years.


MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer.

Suzuki S, Sasajima K, Sato Y, Watanabe H, Matsutani T, Iida S, Hosone M, Tsukui T, Maeda S, Shimizu K, Tajiri T - Br. J. Cancer (2008)

Relationship between MAGE-A family protein (A) and MAGE-A10 mRNA (B) expression and survival duration in all cases.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2480964&req=5

fig3: Relationship between MAGE-A family protein (A) and MAGE-A10 mRNA (B) expression and survival duration in all cases.
Mentions: Kaplan–Meier analysis revealed that group A had significantly shorter survival duration than groups B and C (P<0.0001, each). A 5-year survival rate was 6% in group A, 87% in group B and 100% in group C. Patients with MAGE-A protein and MAGE-A10 gene expression had poor outcome (P<0.0001, each) (Figure 3A and 3B). Only three patients with MAGE-A10 gene expression survived more than 5 years.

Bottom Line: Both protein and gene showed significantly higher expression in group A than those in groups B (6.7, 26.7%) and C (0, 0%) (P=0.0003, P=<0.0001, respectively).MAGE-A10 gene expression was associated with reduced survival duration.The results of this study suggest that MAGE-A10 is a possible target in active immunotherapy for advanced stomach cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Tama-Nagayama Hospital, Nippon Medical School, Tama, Tokyo, Japan. seiji@nms.ac.jp

ABSTRACT
Tumour samples from 71 patients with stomach cancer, 41 patients with liver metastasis (group A) and 15 patients each in stages II-IV (group B) and stage I (group C) without liver metastasis were analysed. MAGE-A protein expression was evaluated by immunohistochemistry using a 6C1 monoclonal antibody and MAGE-A10 mRNA expression was detected by highly sensitive in situ hybridisation using a cRNA probe. Expressions of MAGE-A protein and MAGE-A10 mRNA in group A were detected in 65.9 and 80.5%, respectively. Both protein and gene showed significantly higher expression in group A than those in groups B (6.7, 26.7%) and C (0, 0%) (P=0.0003, P=<0.0001, respectively). MAGE-A10 mRNA expression in liver metastasis was found in eight (88.9%) out of nine patients. The concordant rate between MAGE-A family protein expression and MAGE-A10 mRNA expression in the primary sites was 81.7% (P<0.0001). MAGE-A10 gene expression was associated with reduced survival duration. The results of this study suggest that MAGE-A10 is a possible target in active immunotherapy for advanced stomach cancer.

Show MeSH
Related in: MedlinePlus